I n 2022, over 600,000 people across the world were diagnosed with bladder cancer, a 7.1% increase from 2020, putting their life plans on hold to receive standard of care treatments that are not ...

Cretostimogene treatment shows best-in-class durability of response for BCG-unresponsive non-muscle invasive bladder cancer ...

Learn more about the role of Tuberculosis in cancer and how a simple vaccine supports the immune system to fight it.

There are three types of intravesical immunotherapies for bladder cancer: BCG treatment is the most common immunotherapy for cancer and is often the first-line option for bladder cancer.

rBCG offers an alternative to TICE® BCG amid U.S. shortages, impacting bladder cancer treatment availability. FDA's Expanded Access Program allows investigational rBCG use when no satisfactory ...

A propensity-score matched cohort study found a significantly reduced risk of recurrence of bladder cancer in patients who ...

Two doses of a simple tuberculosis vaccination after surgery helps the immune system fight cancer cells and could greatly improve patient outcomes for the most common type of bladder cancer, according ...

Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 ...

Surgery, chemotherapy, and radiation are some of the treatments for bladder cancer. Treatments used depend on your cancer’s stage and grade, and your age, overall health, and personal preferences.

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC, U.S. prevalence of ~600,000 ...